Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Core Insights - Autolus Therapeutics plc is set to release its third quarter 2025 financial results and operational highlights on November 12, 2025, before the U.S. market opens [1] - A conference call and webcast will be held at 8:30am EST / 1:30pm GMT to discuss the financial results and provide a business update [2] - Autolus specializes in next-generation programmed T cell therapies for cancer and autoimmune diseases, utilizing proprietary T cell programming technologies [3] Company Overview - Autolus Therapeutics plc is an early commercial-stage biopharmaceutical company focused on developing, manufacturing, and delivering T cell therapies [3] - The company has a marketed therapy, AUCATZYL, and a pipeline targeting hematological malignancies, solid tumors, and autoimmune diseases [3] - The company aims to engineer T cell therapies that can better recognize and eliminate target cells by overcoming their defense mechanisms [3]